#1 Clinical Trials Search in Europe

Long-Term Safety Study of Iptacopan for Adults with IgA Nephropathy After Completing a Previous Study, Including ACE Inhibitors and ARBs Drug Combination

3 1 1 1

What is this study about?

This clinical trial is focused on studying the long-term safety and tolerability of a medication called iptacopan in adults with a kidney disease known as IgA nephropathy. IgA nephropathy is a condition where a protein called IgA builds up in the kidneys, causing inflammation and potentially leading to kidney damage. The trial involves participants who have already completed a previous study involving iptacopan.

The purpose of this study is to ensure that iptacopan is safe and well-tolerated over a longer period. Participants will take iptacopan in the form of hard gelatin capsules, which are taken orally. The study will also involve other medications, such as ACE inhibitors and angiotensin II receptor blockers (ARBs), which are commonly used to manage blood pressure and protect kidney function. These medications may be used alone or in combination, depending on the participant’s needs.

Throughout the study, participants will be monitored for any side effects or changes in their health. The study will last for a maximum of 96 weeks, during which time participants will have regular check-ups to assess their kidney function and overall health. The goal is to gather information on how well participants tolerate iptacopan over time and to ensure its safety for long-term use in managing IgA nephropathy.

1 joining the study

Participation begins after signing an informed consent form. This confirms understanding and agreement to comply with the study requirements.

Eligibility requires completion of a previous related study and a specific kidney function level, measured by eGFR, which should be at least 20 mL/min/1.73m².

2 initial assessment

An initial assessment is conducted to ensure all criteria are met, including up-to-date vaccinations against certain infections.

Participants should be on a stable dose of supportive care medication, such as ACE inhibitors or ARBs, unless there are documented reasons for not using them.

3 medication administration

The medication iptacopan is administered in the form of hard gelatin capsules.

The dosage is 200 mg taken twice daily (b.i.d.), which means once in the morning and once in the evening.

4 ongoing monitoring

Regular monitoring is conducted to evaluate the safety and tolerability of the medication. This includes checking for any adverse effects and assessing vital signs.

Laboratory tests are performed periodically to ensure the medication is not causing any harmful effects.

5 evaluation of kidney function

Kidney function is assessed through changes in eGFR, which is a measure of how well the kidneys are filtering blood.

Other evaluations include changes in protein levels in urine, which are indicators of kidney health.

6 completion of the study

The study is designed to continue until 2033, with ongoing assessments to ensure long-term safety and effectiveness of the treatment.

Participants will be informed of any significant findings related to their health during the study.

Who Can Join the Study?

  • You must sign a form to show you understand the study and agree to take part. You should be able to talk with the study doctor and follow the study rules.
  • If you were part of a previous related study, you must have completed all parts of that study.
  • Your eGFR (a test that measures how well your kidneys are working) must be at least 20 mL/min/1.73m². This is calculated using a specific formula based on your ethnic group and local guidelines.
  • The study doctor must believe that you could benefit from taking the study medication, iptacopan, at a dose of 200 mg twice a day.
  • You should be up to date with vaccinations against certain infections like Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. This means you should have received any booster shots needed according to local rules.
  • You must be on a stable dose of medications called ACE inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB), which are recommended for kidney health. If you cannot take these medications due to allergies or other reasons, the study doctor should note this in your records.

Who Cannot Join the Study?

  • Patients who have a different kidney condition other than IgA Nephropathy cannot participate. IgA Nephropathy is a disease that affects the kidneys.
  • Patients who are not within the specified age range for the study cannot participate. The study is open to certain age groups only.
  • Patients who are not able to follow the study procedures or take the study medication as required cannot participate.
  • Patients who have other serious health conditions that might interfere with the study cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who are currently participating in another clinical trial cannot participate.
  • Patients who have had a recent organ transplant cannot participate.
  • Patients who have a history of drug or alcohol abuse cannot participate.
  • Patients who have allergies to the study medication or its ingredients cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Medizinische Hochschule Hannover Hanover Germany
Center For Pediatric And Adolescent Medicine Of The Johannes Gutenberg University Mainz Mainz Germany
Hospital Universitario De Salamanca Salamanca Spain
Azienda Ospedaliera Universitaria Federico II Di Napoli Naples Italy
Technische Universitaet Dresden Dresden Germany
Katholieke Universiteit te Leuven Leuven Belgium
Hospital Universitario De Navarra Pamplona Spain

Other Sites

Site Name City Country Status
Robert Bosch Krankenhaus GmbH Stuttgart Germany
Universitaetsklinikum Aachen AöR Aachen Germany
Universitaetsklinikum Schleswig-Holstein AöR Kiel Germany
Algemeen Ziekenhuis Delta Roeselare Belgium
UNIVERZITETNI KLINICNI CENTER MARIBOR Maribor Slovenia
University Of Debrecen Debrecen Hungary
Odense University Hospital Odense Denmark
Universitaetsklinikum Tuebingen AöR Tuebingen Germany
Hospital Clinic De Barcelona Barcelona Spain
Universitaetsklinikum Magdeburg AöR Magdeburg Germany
Charite Universitaetsmedizin Berlin KöR Berlin Germany
Karolinska University Hospital Solna Sweden
Centre Hospitalier Universitaire De Montpellier Montpellier France
Aalborg University Hospital Aalborg Denmark
Medical Center – University Of Freiburg Freiburg Im Breisgau Germany
Vseobecna Fakultni Nemocnice V Praze Prague Czechia
University Medical Center Ljubljana Ljubljana Slovenia
Rigshospitalet Copenhagen Denmark
University Of Pecs Pecs Hungary
Institut fuer Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH Ulm Germany
Hopital Beaujon Clichy France
University Of Szeged Szeged Hungary
Uvttllummorsttpdrbcgq Eleyz Axk Essen Germany
Uhhmhkosshzo Moawyyh Cuaxlps Gmjxnfpgf Groningen The Netherlands
Fay daoqpcpkko snmrfq stqxjy Kosice Slovakia
Aspliwjnji Punltadi Hzgqdrup Dh Mrjceimst Marseille France
Ajprhecy Uzbyghhvmv Hmzfxios Lorenskog Norway
Hikzy Brtbuo Hf Bergen Norway
Abgvmw Uvtljypifc Hpzpagwa Aarhus Denmark
Agqxqnn Ujexv Sbzldofxq Lswnzg Di Brislmb Bologna Italy
Uorrpocnvc Oe Abiubzi Edegem Belgium

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not recruiting
28.09.2021
Czechia Czechia
Not recruiting
28.09.2021
Denmark Denmark
Not recruiting
28.09.2021
France France
Recruiting
28.09.2021
Germany Germany
Not recruiting
28.09.2021
Hungary Hungary
Not recruiting
28.09.2021
Italy Italy
Not recruiting
28.09.2021
Norway Norway
Not recruiting
28.09.2021
Slovakia Slovakia
Not recruiting
28.09.2021
Slovenia Slovenia
Not recruiting
28.09.2021
Spain Spain
Recruiting
28.09.2021
Sweden Sweden
Not recruiting
28.09.2021
The Netherlands The Netherlands
Not recruiting
28.09.2021

Trial locations

Investigated drugs:

Iptacopan is a medication being studied for its long-term safety and tolerability in adults with primary IgA nephropathy. This trial involves participants who have already completed a previous study with iptacopan. The goal is to ensure that the medication is safe to use over an extended period and to monitor any potential side effects or issues that may arise with its continued use.

Investigated diseases:

IgA Nephropathy – IgA Nephropathy is a kidney disease that occurs when an antibody called immunoglobulin A (IgA) builds up in the kidneys. This buildup can cause inflammation that damages the kidney tissues. Over time, the inflammation can lead to the kidneys losing their ability to filter waste from the blood effectively. Symptoms may include blood in the urine, swelling in the hands and feet, and high blood pressure. The disease progresses at different rates in different individuals, and some may experience a slow decline in kidney function.

Trial ID:
2023-508690-92-00
Protocol code:
CLNP023A2002B
NCT ID:
NCT04557462
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger’s Disease) to Reduce Protein in Urine

    Recruiting

    3 1
    Austria Czechia France Germany Hungary Italy +6

  • Study of felzartamab compared to placebo in adults with IgA nephropathy

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia France Germany +5